Anixa Biosciences Inc ANIX

$2.78 +0.07 (2.58%)

Valuation

Market cap
94,210,000
Revenue TTM
$0
Net income TTM
$-10,930,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
156,800
Avg volume
300,512
Day's range
$2.68 – $2.78
Shares out
34,764,000
Stochastic %K
56%
Beta
0.47
Analysts
Strong Sell
Price target
$9.67

Price

Company profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of...

Show more

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Industry
Biotechnology
Sector
Healthcare
Phone
408 708 9808
Website
https://www.anixa.com
Address
3150 Almaden Expressway, Suite 250, San Jose, United States

Latest news

Stocktwits

SCUBus Oct 23, 1:36 AM
$ANIX Insider purchase: CEO Amit Kumar buys 8,000 shares of ANIX at $2.72 per share today 10/22/2026.
0 replies
dipsandchipssss Oct 22, 11:52 PM
$ANIX CEO Amit Kumar keeps buying — picked up another 8,000 shares today at $2.72. On top of 7,000 @ $2.78 in Sept and 30k+ over the summer. Now holds 680,000 shares. Insider conviction
0 replies
CEOBuysDisclosures Oct 22, 11:50 PM
$ANIX CEO purchased 8,000 shares at $2.72 for a total of $21,760. KUMAR AMIT now owns 680,000 shares. https://ceo-buys.com
0 replies
idkmikes57 Oct 16, 7:19 PM
$ANIX it's one week down, ten percent, almost unbelievable, run, run.
0 replies
frankparch Oct 13, 9:12 PM
$ANIX besides lack of information on phase 2 does anyone know why the recent stock downturn?
1 replies
Perillo1984 Oct 13, 1:14 PM
$ANIX 😜👍👇
0 replies
50shadesoftrades Oct 13, 12:40 PM
$ANIX $ANIX Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference https://www.stocktitan.net/news/ANIX/anixa-biosciences-ovarian-cancer-car-t-therapy-inventor-to-deliver-68mc9bywegyj.html
0 replies
idkmikes57 Oct 12, 8:02 PM
$ANIX low volume!
0 replies